| Drug Name |
Voclosporin |
| Drug ID |
BADD_D02608 |
| Description |
Lupus nephritis (LN) is a type of glomerulonephritis occurring in patients with systemic lupus erythematosus (SLE). LN is a significant cause of renal failure, morbidity, and death in patients with SLE. Within 10 years of being diagnosed with SLE, 5-20% of those suffering from LN develop end-stage kidney disease, a fatal condition. Early and accurate intervention for LN is important in improving clinical outcomes.[A227683]
Voclosporin, marketed as Lupkynis, is a calcineurin-inhibitor immunosuppressant for the treatment of LN.[L31218] This [cyclosporine] A analog was approved by the FDA on January 22, 2021 following promising results in clinical trials. Early intervention with voclosporin coupled with a kidney response is believed to prevent irreversible damage to the kidney and lead to better long-term clinical outcomes for patients with LN.[L31208] Voclosporin has demonstrated a more stable pharmacokinetic and pharmacodynamic relationship than cyclosporine, a higher potency than cyclosporine, and an improved metabolic profile when compared to older calcineurin inhibitors.[L31253] |
| Indications and Usage |
Voclosporin is used in combination with a background immunosuppressive regimen for the treatment of lupus nephritis. Safety has not been established in combination with cyclophosphamide.[L31218] |
| Marketing Status |
approved; investigational |
| ATC Code |
L04AD03 |
| DrugBank ID |
DB11693
|
| KEGG ID |
D09033
|
| MeSH ID |
C484071
|
| PubChem ID |
6918486
|
| TTD Drug ID |
D0L9HX
|
| NDC Product Code |
47848-059; 11014-0480; 75626-001; 11014-0436; 49187-0803 |
| UNII |
2PN063X6B1
|
| Synonyms |
voclosporin | ISATX247 | ISA 247 | ISA-247 | ISA(TX)247 | lupkynis |
